Scancell initiates development of novel DNA vaccine against COVID-19
LONDON: Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, in collaboration with scientists in the newly established…